



101531086
PCT/GB03/001780



INVESTOR IN PEOPLE

The Patent Office
Concept House 11 APR 2005
Cardiff Road


Newport REC'D 22 MAY 2003
South Wales
NP10 8QQ WFO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

22 MAY 2003

LAST AVAILABLE COPY

Request for grant of a patent

Please see the notes on the back of this form. You can also get an Information Leaflet from the Patent Office to help you fill in this form.



29 OCT 02 1307 1 002847
P017706 0.00 0225106.4

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Your reference

HL83615/000/DLB/cv

Patent application number
(The Patent Office will fill in this part)

28 OCT 2002

0225106.4

Full name, address and postcode of the or of each applicant (*underline all surnames*)

Phytopharm plc
Corpus Christi House, 9, West Street,
Godmanchester, Cambridgeshire. PE29 2HY

Patents ADP number (*if you know it*) 0583812300~~4~~

If the applicant is a corporate body, give the country/state of its incorporation United Kingdom

Title of the invention

Synthesis of 3 hydroxy-5 β -steroids

Name of your agent (*if you have one*)

Haseltine Lake

"Address for service" in the United Kingdom to which all correspondence should be sent (*including the postcode*)

Imperial House
15-19 Kingsway
London
WC2B 6UD

Patents ADP number (*if you know it*)

34001

If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (*if you know it*) **the or each application number**

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer Yes or No*)

Yes

- a) *any applicant named in part 3 is not an inventor, or*
- b) *there is an inventor who is not named as an applicant, or*
- c) *any named applicant is a corporate body.*
See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

0

Description

9

Claim(s)

—

Abstract

—

Drawing(s)

8

S

X4

10. If you are also filing any of the following, state how many against each item.

Priority documents

0

Translations of priority documents

0

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

0

Request for preliminary examination and search (Patents Form 9/77)

0

Request for substantive examination (Patents Form 10/77)

0

Any other documents
(please specify)

0

11.

I/We request the grant of a patent on the basis of this applic

Signature *Marelthie Lake Brown*

Date 28.10.

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr David L Brown

[0117] 910 3200

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. I will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

Synthesis of 3 hydroxy-5 β -steroids

The present invention relates to the synthesis of 3-hydroxy-5 β -steroids.

It has been shown that steroids possessing a 5 β -hydrogen have utility in the treatment of cognitive dysfunction (WO 01/49703, WO 02/079221, WO 01/23406). The present invention has been made in the synthesis of said 5 β steroids, and in the synthesis of 3-hydroxy-5 β -steroids generally. The present invention enables such steroids to be prepared with improved efficiency and with controllable stereospecificity as between the 3 α and 3 β isomers.


According to a first aspect of the present invention, there is provided a method of preparing 3-hydroxy steroids, which comprises reducing a 3-keto steroid using as reducing agent a selectride or an aluminium hydride. Generally speaking, the selectride reducing agent produces predominantly 3 β hydroxy steroids (e.g. smilagenin and the like), and the aluminium hydride produces predominantly 3 α steroids (e.g. epismilagenin and the like).

The term "selectride" means any alkali metal tri-alkyl or tri-aryl borohydride reducing agents such as lithium tri(sec-butyl) borohydride, lithium tris-amyl borohydride or lithium triphenyl borohydride, or the corresponding reducing agents with lithium replaced by potassium. Alkyl groups preferably contain from 1 to 7 carbon atoms. Aryl groups preferably contain from 6 to 12 carbon atoms and may be alkyl-substituted.

The term "aluminium hydride" means any reducing agent containing aluminium and hydride moieties, optionally with other moieties such as lithium or organic groups (e.g. alkyl or alkoxy, suitably containing from 1 to 7 carbon atoms) also present, such as lithium aluminium hydride (lithal), dibutyl aluminium hydride or lithium aluminium t-butoxy hydride.

The said reduction is described in more detail, without limitation and purely by way of illustration, as Stage 3 of the overall process described below.

More particularly, but not exclusively, we have developed a process for the synthesis of either smilagenin and epismilagenin from diosgenin utilising selective reductions to control stereochemistry. Scheme 1 shows the process as developed for the synthesis of smilagenin, utilising an oxidation to afford the $\alpha\beta$ -unsaturated ketone, diosgenone, followed by catalytic reduction to introduce stereoselectively the 5 β -hydrogen followed by selective hydride reduction to introduce the 3 β -hydroxyl group stereoselectively. The direct reduction of diosgenin using palladium on carbon as a catalyst gives predominantly the 5 α -product, tigogenin.



Scheme 1: Manufacturing route for smilagenin from diosgenin

Details of Stage 1

Stage 1 of the synthetic route utilises a modified Oppenauer reaction (R. V. Oppenauer, *Rec Trav. Chim.* 56, 137 (1937)). This reaction is the aluminium alkoxide catalysed oxidation of a secondary alcohol to the corresponding ketone.

Whilst the oxidation of diosgenin to diosgenone has been described in the literature, practical considerations have prevented the process being of much utility. It has been discovered by the applicant that the use of 0.5 equivalents of aluminium isopropoxide in a combination of 5 volumes of 2-butanone and 5 volumes of toluene with the reaction heated to between 60°C and the reflux temperature of the solvent effected oxidation of diosgenin in a timely manner. Aluminium salts are removed by dissolution in 1M hydrochloric acid. The use of toluene as a co-solvent aids in the isolation, after acid work-up, of the product, diosgenone, in typically 55-70% yield as a clean product.

Marker et al (Marker *et al.*, 1940) described the oxidation of diosgenin by the method of Oppenauer, using cyclohexanone and aluminium *iso*-propoxide (5 equiv.) in toluene. The reaction was very dilute (58 volumes; excluding work-ups) and is impractical for economic processing on a large-scale. The use of a large excess of aluminium *iso*-propoxide is not desirable, since this will lead to an increased effluent burden. Irismetov has also described the oxidation by diosgenin by the method of Oppenauer, using cyclohexanone and aluminium

iso-propoxide (1 equiv.) in toluene (Irismetov & Goryaev, 1981). Again this process suffers from low dilution, though the amount of aluminium *iso*-propoxide has been reduced to the stoichiometric amount. Djerrasi has reviewed the Oppenauer oxidation (Djerassi, 1951). The introduction of the combination of cyclohexanone and toluene (or xylene) provided significantly shorter reaction times when compared to the use of acetone and benzene in the original work of Oppenauer. Cyclohexanone has found particular use in the field of steroids since it can be removed from the product by steam distillation. Djerrasi stated that 2-butanone has found utility though it generally does not offer advantages over acetone or cyclohexanone. The use of 1-3 equivalents of aluminium *iso*-propoxide were typically used.

It is surprising that the use of sub-stoichiometric amounts of aluminium *iso*-propoxide in conjunction with 2-butanone and toluene as reaction solvent affords a similar yield of diosgenone in a similar timeframe to the use of cyclohexanone and stoichiometric amounts of aluminium *iso*-propoxide.

The present method provides cost savings on reagents and disposal charges. 2-Butanone has a lower boiling point than cyclohexanone (80°C cf. $154\text{-}156^{\circ}\text{C}$) and is therefore easier to remove from the reaction mixture.

Details of Stage 2

Stage 2 of the manufacturing method for smilagenin (Scheme 1) utilises the reduction of the double bond of the $\alpha\beta$ -unsaturated carbonyl. To effect the desired β -face attack of hydrogen, a number of catalysts and conditions were screened. Initial work investigated the method as described in the literature wherein the reduction is effected by hydrogen at 1 bar in the presence of 10% palladium on carbon and 20% potassium hydroxide in methanol as solvent. Whilst this effected the desired selectivity ($5\beta:5\alpha = 93:7$), and was of commercial utility, the avoidance of alkali would afford simpler work-up conditions. Marker has shown that the reduction of diosgenone to smilagenone can be achieved with palladium-barium sulphate catalyst in diethyl ether solution under hydrogen (i.e. 10 psi). The low concentration (500 volumes; normal processing volumes are in the range of 5-30 volumes) and high catalyst loading (1000%; normal catalyst loadings are in the range 1-20%) render the process as described unfeasible and uneconomical for large-scale work. An additional consideration is that diethyl ether is unsuitable for large-scale work for safety reasons. Table 1 details the various conditions investigated for the reduction using palladium on barium sulphate as the catalyst.

Other workers have also investigated the reduction of diosgenone to smilagenone. Djerassi reduced diosgenone in ethanol (450 ml) over pre-reduced 10% Pd-C (0.8 g) at atmospheric pressure. Crude smilagenone was isolated by precipitation with water and recrystallised from chloroform/methanol to furnish pure smilagenone (7.2 g, 72%) with a melting point of $179\text{-}183^{\circ}\text{C}$. The yield was not changed when the reaction was carried out in the presence of potassium hydroxide (3 g). An analytically pure sample melted at $186\text{-}188^{\circ}\text{C}$ (Djerassi *et al.*, 1952).

In the pregnane series Suvorov has found that pyridine has a marked effect upon the outcome of such hydrogenation reactions. Typically, in this work the catalyst of choice was 10% palladium on calcium carbonate (Pd-CaCO₃). In such cases the selectivity was found to be markedly superior to those reactions run in alcoholic solvents, even with the addition of caustic (Suvorov & Yaroslavtseva, 1961). The work-up employed in this study involved quenching onto dilute hydrochloric acid and extraction of the product into chloroform. The organic extract was washed with dilute hydrochloric acid, 8% aqueous sodium bicarbonate solution and water until neutral to litmus. Such methods lead to the production of large

amounts of aqueous containing pyridine and halogenated solvents effluent that require disposal, adding to the cost of processing.

Irismetov demonstrated that high selectivity could be achieved in the reduction of diosgenone to smilagenone. In this work diosgenone (1 g) was hydrogenated over 5% Pd-CaCO₃ (1 g) in pyridine (30 ml) at atmospheric pressure. After filtration to remove the catalyst and solvent evaporation the residue was crystallised from alcohol to afford a solid melting at 209-211°C. No yield is given (Irismetov & Goryaev, 1981). For large-scale production this work suffers from high catalyst loadings (100%) and moderately dilute solutions. Pyridine is a noxious solvent and is more generally used in stoichiometric amounts as an acid scavenger in large-scale work. The requirement to evaporate to dryness is not preferred on large-scale.

US patent 736,818 makes a claim for the reduction of 3-keto- Δ^4 -steroids to 5 β -H steroids with a palladium catalyst, in the presence of an inorganic base and in an anhydrous medium. The preferred solvent is methanol and the preferred base is potassium hydroxide. Diosgenone is not exemplified. We find that diosgenone is poorly soluble in alcohols (specifically ethanol), which would render this process very dilute. Such a method also requires an extractive work-up procedure.

US patent 763,301 makes reference to the utility of alkali (*i.e.* sodium or potassium hydroxide) in increasing the amount of 5 β -H product in the reduction of 3-keto- Δ^4 -steroids. This patent makes a specific claim for the utility of triethylamine in this context. Of the solvents chosen ethanol, ether, ethyl acetate and methylcyclohexane are cited, with 1,4-dioxane being the preferred solvent.

Table 1: Solvent screening studies with Pd-BaSO₄

Entry	Time min	Vol. ml	Solvent	Yield %	Smilagenone %	Diosgenone %	Diosgenone %	Effluent mg/l
1	4	5	THF	100	95.7	2.1	<0.1	1.2
2	12	20	Et ₂ O	51	86.5	3.7	7.3	1.5
3	15	15	TBME	43	91.1	7.6	0.3	1.0
4	7	15	DEM	54	91.1	6.5	0	2.2
5	16	10	1,4-dioxan	94	95.7	2.9	-	1.4
6	7	15	IPA	16	67	26.1	0.5	4.8
7	4	15	EtOAc	70	93.2	4.2	0.4	1.8
8	7	15	Acetone	28	82.6	13.0	0.5	3.7
9	6	15	MIBK	79	92.4	13.0	1.5	1.6
10	3	15	cyclohexane	52	92.6	6.7	-	0.7
11	10	5	Toluene	100	92.1	2.5	4.6	0.8
12 ¹		15	NMP	100	72	9.0	17.5	1.1
13 ¹	2	5	THF	100	95.7	2.1	<0.1	1.2
14 ¹	2	5/1	THF/20% pyridine					

Note: 1. the catalyst was from Alfa

Initial method development work examined two solvents in the hydrogenation reaction, namely ethanol and tetrahydrofuran (THF). The latter solvent became the solvent of choice since it offered an improved solubility of diosgenone, resulting in a higher throughput process, and provided a simple work-up when compared to the ethanol/aqueous sodium hydroxide system. The work-up consisted of concentration of the reaction mixture and purification by reslurrying the residue. A number of solvents were effective in achieving partial purification of the smilagenone. Surprisingly, later work demonstrated the ability to telescope stages 2 and 3 by removing the catalyst by filtration and reduction of the solution of smilagenone in THF with L-selectride to furnish smilagenin. It was demonstrated that the impurities formed in the process (epitigogenin) could be readily removed at this stage.

The goals of the solvent screening work were to see if other solvents offered process advantages over THF in terms of selectivity, concentration and general processing characteristics. A diverse range of solvents was selected and screened on a 5 g scale under 1 atmosphere of hydrogen at ambient temperature. Each reaction used a 20% loading of 5% Pd-BaSO₄ (r) purchased from Sigma-Aldrich unless otherwise stated. For those reactions that required 15 volumes or more of solvent not all of the diosgenone was fully dissolved and the reaction was carried out on the resultant suspension. The results of this study are recorded in table 1. The filter cake from these reactions was washed well with dichloromethane (DCM) to ensure that a complete mass balance was achieved. The results of this study are recorded in table 2.

Table 2: Product recovery from Celite filter cake

Entry	Ref.	Solvent	Yield %	Smilagenone	Tigogenone	Diosgenone	Tigogenin
1	KST/99	Et ₂ O	27	93.7	0.4	5.5	0.3
2	KST/101	TBME	55	99.0	0.7	0.3	-
3	CRW031	IPA	72	93.6	0.6	4.7	0.8
4	CRW032	EtOAc	24	99.0	0.2	0.7	0
5	CRW029	acetone	67	97.2	0.3	2.0	0.4
7	KST/102	MIBK	17	96.3	0.3	2.8	0.3
8	KST/103	Cyclohexane	41	99.0	0.3	0.2	-

Other conditions and catalysts were screened in order to investigate whether improvements in selectivity could be achieved. From Table 3 it is apparent that an increase in pressure to 2 bar resulted in a lower selectivity for the process. The use of the unreduced form of Pd-BaSO₄ also gave lower selectivity. The use of Pd-CaCO₃ in THF also gave a useful process; the selectivity of which could be further improved by using pyridine as solvent (Suvorov & Yaroslavtseva, 1961). The latter reaction was worked up by quenching onto dilute hydrochloric acid, filtration of the resultant precipitate and washing with water to furnish smilagenone in 80% yield. Overall, this does not represent a superior process to that using THF for large-scale manufacture due to the increased processing required. Surprisingly, the unreduced form of this catalyst was found to be less selective.

Table 3: General screening studies

Entry	Scale/g	Solvent/Catalyst	Smilagenone	Tigogenone	Diosgenone	Tigogenin
1	10	Pd-BaSO ₄ /THF/2 bar	87.8	7.3	1.8	1.5
2	100	Pd-BaSO ₄ (u)/THF				

3	20	Pd-CaCO ₃ (r)/THF	91.4	6.9	-	1.7
4		Pd-CaCO ₃ (r)/pyridine	94.7	2.6	0.8	1.5
5	20	Pd-CaCO ₃ (u)/THF	81.1	14.2	-	1.7

Previously smilagenone had been purified by a reslurry in cyclohexane. During the development work MEK and IPA had also been found to be effective but were not further explored. The aim of this work was to examine purification of smilagenone by a formal recrystallisation from each of these solvents. From table 4 it is apparent that each of these solvents is able to raise the purity of smilagenone to >97%, with MEK being the most volume efficient.

Table 4: Recrystallisation of crude smilagenone

Entry	Solvent	Volumes	Yield/%	Smilagenone	Tigogenone	Diosgenone	Tigogenone
1	Input	-		91.35	5.15	1.71	1.27
2	MEK	5	70	97.77	1.20	0.39	0.51
3	Cyclohexane	8	72	97.71	1.10	0.33	0.57
4	IPA	12		97.40	1.35	0.37	0.71

We have found that palladium on barium sulphate and palladium on calcium carbonate are particularly effective catalysts. It has been discovered that pre-reduced forms of the catalysts are superior to the unreduced forms.

THF and toluene have been found to be useful solvents for the reaction and give a similar selectivity to the use of pyridine as solvent. Both solvents are advantageous over pyridine as a process solvent on the basis of cost, work-up and disposal. The use of THF in particular has been shown to avoid the need for work-up and telescoping of the reaction mixture directly into stage 3 to furnish smilagenin of good purity. This avoids the need for work-up, isolation and drying of the intermediate smilagenone, providing savings in time and equipment usage and therefore expected improvements in manufacturing costs.

The use of the above catalysts in combination with THF or toluene represent a particularly useful combination, in the absence of any added base. Other replacement solvents for ether, such as *tert*-butyl methyl ether or diethoxymethane, are less efficient than THF due to the lower solubility of diosgenone in these solvents.

Discussion of Stage 3

Stage 3 of the overall scheme for the production of smilagenin from diosgenin required the selective production of the 3 β -hydroxyl group. By contrast, if epismilagenin was to be produced a selective reduction to afford the 3 α -hydroxyl functionality.

Marker (1940) effected the reduction of smilagenone to smilagenin by the Meerwein-Ponndorf-Verly (MVP) method, though no yield was given.

Djerassi repeated the work of Marker to produce smilagenone by reduction of diosgenone. The smilagenone was subsequently reduced with LAH to afford almost exclusive formation of epismilagenin (Djerassi *et al.*, 1952)

Screening of reagents for this transformation indicates that L-selectride and other reagents in this family (e.g. K-selectride, LS-selectride and potassium triphenylborohydride) are effective in the reduction of smilagenone to smilagenin. These reagents not only have application only in the production of smilagenin, but other 3β -hydroxy- 5β -steroids.

During the course of this work a number of reagents have been identified that lead to useful selectivity for the conversion of smilagenone into epismilagenin.

It has been discovered that either a 3α or 3β hydroxyl could be formed by the correct choice of hydride reducing agent. Whilst a number of reagents have been discovered to effect selectivity to either afford smilagenin or epismilagenin, two that have so far afforded the most utility are lithium tri-*t*-butoxyaluminium hydride to afford selectively the 3α -hydroxyl, e.g. epismilagenin, and L-selectride (lithium tri-sec-butylborohydride) to selectively produce the 3β -hydroxyl e.g. smilagenin. Table 5 lists reagents used in the reduction of smilagenone.

Table 5 Selectivity in the reduction of smilagenone.

Note: Reactions performed in THF unless otherwise noted.

US patent 3,875,195 with a application priority date of 18th November 1972 in Germany, discloses the use of Raney-Nickel and hydrogen in a carboxylic acid solvent under high pressure for the preparation of 3 β -hydroxy-5 β -H-steroids.

Brown's paper (Brown et al, 1972) disclosing the use of L-selectride was published in the Journal of the American Chemical Society on 4th October 1972. The failure of the above workers to employ L-selectride provides evidence that this use of this reagent for this transformation is not obvious.

EXAMPLES

Example 1

Synthesis of diosgenone from diosgenin

Diosgenin (1010 g, 2.44 mol), aluminium *iso*-propoxide (298.5 g, 1.05 mol, 0.44 equiv.) and butanone (5000 ml) were suspended in toluene (5000 ml, 5 volumes) and the reaction heated to reflux (88-90°C) for 7 hours.

A solution of 37% hydrochloric acid (1000 ml) in water (4000 ml) was added to the reaction mixture at 25-35°C and the mixture stirred for at least 30 minutes. The acidic aqueous phase is separated and re-extracted with toluene (2000 ml). The combined organic layers were washed with water (2 x 2000 ml) and evaporated to low volume at 50-75°C and 10-100 mbar, collecting ca. 8500 ml of distillate. Heptane (10,000 ml) was added over 40 minutes at 60-75°C. The slurry was held at 75°C for 40 minutes and cooled to -5 to 5°C and stirred for 3 hours. The product was filtered off and washed with heptane (1000 ml) at 5°C. The product was oven dried at 40-60°C to afford diosgenone (728.6 g, 72%).

Example 2

Synthesis of smilagenone from diosgenone

Diosgenone (700 g) was dissolved in tetrahydrofuran (4500 ml) and purged with nitrogen. The mixture was treated with activated carbon (35 g) and hydrogenated over 5% Pd/BaSO₄ (reduced) (35 g) at 25°C, 2.5 barg hydrogen until hydrogen uptake ceased. The catalyst was filtered off.

The smilagenone can be isolated by concentration and precipitation by addition of water, or the solution can be processed into stage 3. 37 kg of diosgenone has been processed in two batches to provide after filtration of the catalyst and work-up by the aqueous drown-out method to furnish 34.4 kg (92% yield) smilagenone.

Example 3

Synthesis of smilagenin from smilagenone


Smilagenone (657 g) was dissolved in tetrahydrofuran (4000 ml) and the solution purged with nitrogen and cooled to provide an internal temperature of *ca.*-10°C. L-Selectride (2400 ml 1M in THF) was added over *ca.* 50 minutes and stirred for 90 minutes. A solution of citric acid (600 g) in water (2000 ml) was added slowly, maintaining the temperature below 0°C. The mixture was allowed to warm to ambient temperature and stirred for 30 minutes. The aqueous layer was separated and extracted with dichloromethane (2000 ml) and the layers separated. The aqueous layer was extracted with dichloromethane (1500 ml). The combined organic extracts were washed with water (4000 ml) and dried over MgSO₄. The organic extracts were evaporated to dryness to yield smilagenin.

REFERENCES

- ANDERSON, N. (2000) *Practical process research and development*. Academic Press.
- BOAZ, N. W. & VENEPALLI, B. (2001). Applications of diethoxymethane as a versatile process solvent and unique reagent in organic synthesis. *Organic Process Res & Dev.*, 5, 127-131.
- MARKER, R., TSUKAMOTO, T., & TURNER, DL. (1940). Sterols C Diosgenin. *J. Am. Chem. Soc.* 2525-2532.
- SUVOROV, N. N. & YAROSLAVTSEVA, Z. A. (1961). Steroids IX. The stereospecificity of the hydrogenation of steroid Δ^4 -3-keto unsaturated compounds. *Zhurnal Obshchey Khimi (USSR)*, 31, 1372-1377.
- BROWN, H. C. & KRISHNAMURTHY, S. (1972). Lithium Tri-sec-butylborohydride. A new reagent for the reduction of cyclic and bicyclic ketones with super stereoselectivity. A remarkably simple and practical procedure for the conversion of ketones to alcohols in exceptionally high stereochemical purity. *J. Am. Chem. Soc.*, 94, 7159-7161.
- DJERASSI, C. (1951) The Oppenauer oxidation. In *Organic Reactions*. pp. 207-272.
- DJERASSI, C., YASHIN, R., & ROSENKRANTZ, G. (1952). Steroidal saponins. XIII. Δ^{22} isospirosten- 3α -ol. *J. Am. Chem Soc.*, 74, 422-424.
- IRISMETOV, M. P. & GORYAEV, M. I. (1981). Modified steroids. IX. Synthesis of A/B-cis and A/B-trans derivatives and study of proton NMR spectra in a series of diosgenin steroid compounds. *Izv. Akad. Nauk Kaz. SSR, Ser. Khim.*, 2, 47-52.

1/8

Stage 1



Stage I (continued) ^{2 / 8}


Oppenauer Oxidation

- Reaction is an equilibrium between the Alcohol and a Ketone used in excess as solvent. Ketone used in this case was 2-Butanone
- Toluene used as a co-solvent to aid Isolation
- 0.5 equivalents Aluminium Isopropoxide needed - even though it is a catalyst
- Reaction took 6 hours at reflux - no ΔHr hazard
- 86% product formed with 3% SM & trace impurities
- Aluminium salts removed by dissolution in 1M HCl
- 60% isolated yield of clean product

3/8

Stage 2

Selective Hydrogenation



Ratio 5-Beta : S-Alpha
93 : 7


**Selective reduction of double bond
to give 5-Beta configuration**

Stage 2 (continued) 4/8

Selective Hydrogenation

- Conditions utilised were:-
 - 10% Pd/C catalyst (3% loading), 20% KOH solution
 - Ethanol as co-solvent
 - 1 Barg Hydrogen pressure at 20°C
- $\Delta H = -120 \text{ kJ.mol}^{-1}$ (CHETAH) \Rightarrow Inherently Safe
- Isolated yield 85%. Ratio 5-Beta to 5-Alpha 93:7
- Key to selectivity is fast hydrogenation using Blazzi technology
- Isolated yield and isomer ratio exactly mimicked laboratory-scale (2L) results

Selective Hydrogenation



Selective reduction of double bond
to give 5-Beta configuration

Stage 2 (continued) 5/8


Selective Hydrogenation

- Conditions utilised were:-
 - 5% Pd on BaSO₄
 - Tetrahydrofuran solvent
 - 2.5 Barg Hydrogen pressure at 25°C
- Conditions needed to be changed owing to lack of solubility of substrate in 2-phase KOH/Ethanol mix
- Same selectivity achieved as for other system
(Ratio 5-Beta to 5-Alpha 93:7)
- Rapid hydrogenation using Blazzi again key to achieving selectivity

6/8

Stage 3

Reduction Using LiAl(*t*-BuO)₃H




Stereoselective reduction to 3-Alpha Hydroxy
Lower face is hindered, reagent delivers Hydride to top face

Stage 3 (continued) 7/8

Reduction using LiAl(t-BuO)₃H

- 1.1 equivalents Hydride employed. This reagent chosen to give selectivity
- Run at -25°C to further enhance selectivity
- $\Delta H = -130 \text{ kJ.mol}^{-1}$, $T_{ad} = -50^\circ\text{C} \Rightarrow$ Inherently Safe
- No Hydrogen evolved during the addition of Hydride (apart from that due to initial reaction with Water)
- Quench controlled using Na_2SO_4 solution (Exo + $\text{H}_2\uparrow$)
- Quench temperature critical to obtain filterable solid (Aluminum salts)
- Product precipitated by addition of Water (49-53%)
- Selectivity of desired 3-Alpha Hydroxy = 96:4

Selective Reduction using Lithium Selectride



Stereoselective reduction to 3-Beta Hydroxy
Lower face is hindered, reagent delivers Hydride to lower face

8 / 8

Stage 3 (continued)

Selective Reduction using Lithium Selectride

- Selective reduction to give opposite configuration of the Alcohol from $\text{LiAl}(\text{i-BuO})_3\text{H}$
- Reaction run in Tetrahydrofuran at -10°C
- Selectivity of 3-Beta to 3-Alpha of 95:5
- Work-up by quench into acid, acid washes, solvent extraction, further washes then solvent replacement
- Isolated yield: 80% of 90% pure material (~5% SM)
- Recrystallised to give 99% pure material

THE PATENT OFFICE

13 MAY 2003

**Received in Patents
Examination Unit**

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.